Brammer Bio

What Brammer Bio does

Brammer Bio is a viral vector contract development and manufacturing organization (CDMO) specializing in gene therapy and cell therapy manufacturing, acquired by Thermo Fisher Scientific in 2019 for $1.7 billion and now operating as part of Thermo Fisher's Patheon pharmaceutical services division under the Viral Vector Services (VVS) brand. The company provides end-to-end services spanning process development, analytical development, clinical and commercial manufacturing, fill-finish, regulatory support, and cold chain logistics for biotechnology and pharmaceutical customers developing gene therapies and gene-modified cell therapies. Its customer base includes gene therapy developers (such as bluebird bio and NysnoBio) and cell therapy companies requiring lentiviral vectors for CAR-T applications.

The core technology platform supports multiple viral vector types including adeno-associated virus (AAV), lentiviral (LV), adenoviral, retroviral, herpesviral, MVA, VSV, and virus-like particles across both suspension (up to 2,000L) and adherent cell culture platforms. Proprietary capabilities include the Rapid Development Framework™ (9-month GMP delivery timeline), triple transfection and infection techniques for AAV across serotypes, stable packaging cell line-based processes for lentiviral vectors, chromatography-based purification with full capsid separation, and semi/fully automated fill-finish lines. The infrastructure spans over 555,000 square feet across four sites: Plainville, MA (290,000 ft² for end-to-end viral vector services), Cambridge, MA (140,000 ft² for late-phase and commercial manufacturing since 2018, with first commercial license in Q1 2021), Seneffe, Belgium (34,000 ft² with EMA approval history), and Gosselies, Belgium (8,300 ft² for process development and analytical work).

Revenue is generated through long-term contract fees for clinical and commercial CDMO services, with quote-based pricing driven by project-specific requirements, scale, and contract terms. The go-to-market model is enterprise direct sales with dedicated account teams, technical sales representatives, and regulatory affairs specialists engaging biotech and pharmaceutical customers. The company has manufactured 1,100+ viral vector lots cumulatively, holds 3 commercially approved products, and is conducting 8 upcoming/ongoing Process Performance Qualification (PPQ) batches.

Name

Brammer Bio

Legal name

Brammer Bio

Website

https://brammerbio.com

Company type

Private

Founded year

2015

Operating status

Acquired

Headcount range

501–1,000 employees

Short description

Brammer Bio is a viral vector CDMO providing end-to-end gene and cell therapy manufacturing services across AAV, lentiviral, and other vector types, now operating within Thermo Fisher Scientific's Patheon pharmaceutical services division under the Viral Vector Services brand.

Ownership category

akta.pro rank

Product category

Viral Vector Contract Development and Manufacturing (CDMO)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB)

akta.pro secondary industries

Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral) (HLAAAKAD), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)

Keywords

• Viral vector manufacturing
• Gene therapy CDMO
• AAV vector production
• Lentiviral vector services
• Cell therapy manufacturing

Headquarters

HQ city

Lexington

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Viral Vector CDMO Services: Contract development and manufacturing organization providing end-to-end services for viral vector development and commercialization. Revenue generated through long-term manufacturing contracts for clinical trial material and commercial product supply. Services span process development, analytical development, clinical manufacturing, commercial manufacturing, and fill-finish services. Customers include biotech and pharmaceutical companies developing gene therapies and gene-modified cell therapies.
2. M&A Acquisition Value: Brammer Bio was acquired by ThermoFisher Scientific for $1.7 billion as part of their strategy to expand cell and gene therapy CDMO capabilities. The company now operates as part of Thermo Fisher's Viral Vector Services (VVS) division under the Patheon brand.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Brammer Bio is a contract development and manufacturing organization (CDMO) that develops and produces viral vectors—primarily adeno-associated virus (AAV) and lentiviral vectors—for gene therapy and gene-modified cell therapy programs. The company delivers end-to-end services including upstream and downstream process development, analytical development, CGMP clinical and commercial manufacturing on adherent and suspension platforms up to 2,000L, aseptic fill-finish, and global regulatory support.

Product overview

Brammer Bio, acquired by Thermo Fisher Scientific in 2019 for $1.7 billion, is a viral vector CDMO specializing in gene therapy manufacturing. The company's offerings are now integrated into Patheon Pharma Services as part of Thermo Fisher Scientific's Advanced Therapies division. The portfolio includes Viral Vector Manufacturing Services (VVS) as the core offering, with sub-products covering Adeno-Associated Virus (AAV) vectors and Lentiviral vectors (LV), plus supporting modules including Rapid Development Framework™ for accelerated 9-month GMP delivery, Process Development Services, Regulatory Services, and Cold Chain Logistics. The services span from early development through commercial manufacturing, with facilities in the US (Plainville, MA; Cambridge, MA) and Europe (Seneffe, Belgium; Gosselies, Belgium), leveraging expertise from Brammer Bio, Henogen S.A., and Fisher Clinical Services.

Differentiator

Problem solved

Functional benefit

Products and services

• Viral Vector Manufacturing Services (VVS) End-to-end contract development and manufacturing services for viral vectors used in gene therapies and gene-modified cell therapies, covering process and analytical development, CGMP clinical and commercial manufacturing, aseptic fill-finish, and global regulatory support for biotech and pharmaceutical customers.
• Adeno-Associated Virus (AAV) Vector Manufacturing Process development and CGMP manufacturing of adeno-associated virus vectors across multiple serotypes using triple transfection and infection techniques on adherent and suspension platforms, for pre-clinical, clinical, and commercial gene therapy applications.
• Lentiviral Vector (LV) Manufacturing Process development and CGMP manufacturing of lentiviral vectors using both transient transfection and stable packaging cell line-based processes on adherent and suspension platforms, supporting CAR-T and other gene-modified cell therapies.

Quantifiable outcome

• GMP drug product delivery in as little as 9 months using Rapid Development Framework
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered core.

• ThermoFisher ScientificcoreOthers · 1 May 2019ThermoFisher Scientific acquired Brammer Bio for $1.7 billion in 2019 as a strategic acquisition to expand its cell and gene therapy CDMO capabilities. Brammer Bio's viral vector manufacturing expertise was integrated into Thermo Fisher's Patheon division to create a leading viral vector services offering. The company now operates as part of Thermo Fisher's Viral Vector Services (VVS) division.
• Henogen S.A.coreStrategic or Co-development PartnerViral vector knowledge and experience from Henogen S.A. has been leveraged within Thermo Fisher's Viral Vector Services. Henogen contributed expertise in virus and viral vector manufacturing that enhances the combined organization's capabilities across multiple viral vector types.
• Fisher Clinical ServicescoreStrategic or Co-development PartnerClinical trial capabilities from Fisher Clinical Services have been integrated into the Viral Vector Services offering, providing global clinical supply chain, cold chain logistics, and distribution capabilities to support customers throughout clinical development.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Lonza Cell & Gene Technologies: One of the largest CDMOs globally with significant viral vector manufacturing capacity for gene therapies. Directly competes with Brammer Bio in AAV and lentiviral vector CDMO services across US and European markets.
• Vibalogics: Specialized CDMO focused on virus and viral vector manufacturing (oncolytic, vaccine, gene therapy). Directly competes with Brammer Bio in viral vector CDMO services, particularly for niche and complex programs.
• Yposkesi: European viral vector CDMO specializing in AAV and lentiviral vector manufacturing for gene therapy. Comparable to Brammer Bio in viral vector services though operating primarily in the European market with smaller scale.
• AGC Biologics: CDMO offering viral vector and cell therapy manufacturing services. Competes with Brammer Bio in AAV and lentiviral vector manufacturing for gene therapy clinical and commercial programs.
• Charles River Laboratories: CDMO with viral vector manufacturing capabilities following acquisitions of Cognate BioServices and Vigene Biosciences. Competes directly with Brammer Bio in viral vector CDMO services for gene and cell therapy developers.
• WuXi AppTec: Global CDMO offering cell and gene therapy manufacturing services including viral vector production. Direct competitor with comparable service offerings across process development, manufacturing, and fill-finish.
• Catalent: Global CDMO with leading cell and gene therapy manufacturing capabilities, including viral vector production. Direct competitor to Brammer Bio's AAV and lentiviral vector CDMO services across clinical and commercial stages.

Broad incumbents

• Samsung Biologics: Large-scale biologics CDMO expanding into cell and gene therapy services. While broader in scope, Samsung represents an emerging threat in viral vector manufacturing as it invests in gene therapy CDMO capabilities.
• Patheon Pharma Services (Thermo Fisher): Broader pharmaceutical services division of Thermo Fisher, now housing Brammer Bio. While Brammer Bio is part of Patheon, the wider division provides context on its integration into Thermo Fisher's broader CDMO portfolio.

Emerging players

• Eurofins CDMO: Global CDMO offering biologics and advanced therapy manufacturing services including viral vectors. Comparable peer in the viral vector CDMO space though with more diversified service offerings beyond gene therapy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/brammer-bio-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Brammer Bio